Maravai LifeSciences Holdings (MRVI) Stock Overview
A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MRVI from our risk checks.
MRVI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.02 |
| 52 Week High | US$5.21 |
| 52 Week Low | US$1.99 |
| Beta | 0.71 |
| 1 Month Change | 3.51% |
| 3 Month Change | 38.29% |
| 1 Year Change | 110.04% |
| 3 Year Change | -61.47% |
| 5 Year Change | -88.77% |
| Change since IPO | -83.18% |
Recent News & Updates
Narrative Update • May 29
MRVI: Higher 2026 Outlook And Revised Assumptions Will Likely Limit Further Upside
Analysts have lifted their price target on Maravai LifeSciences Holdings by $1.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E that are reflected in recent Street research. Analyst Commentary The updated price target, raised by $1.50, reflects refreshed assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E that appear in recent Street research.Seeking Alpha • May 18
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable
Summary Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings. Despite lumpy revenues and China headwinds, MRVI’s long-term growth prospects and sector correlation support a bullish outlook. Read the full article on Seeking Alpha
Narrative Update • May 14
MRVI: Future Upside Will Depend On Executing Updated 2026 Revenue Guidance
Analysts have raised their price targets on Maravai LifeSciences Holdings by increments of $1 and $1.50 after updating models for fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. This Narrative Update reflects those revised inputs.Narrative Update • Apr 28
MRVI: Q4 Beat And Raised Guidance Will Likely Cap Near Term Upside
Analysts have adjusted their view on Maravai LifeSciences Holdings, with the average price target moving from $2 to $3 as updated models incorporate Q4 results that modestly beat consensus and reflect revised assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Even with the price target move to US$3, bearish analysts are signaling that expectations remain restrained.Recent updates
Narrative Update • May 29
MRVI: Higher 2026 Outlook And Revised Assumptions Will Likely Limit Further Upside
Analysts have lifted their price target on Maravai LifeSciences Holdings by $1.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E that are reflected in recent Street research. Analyst Commentary The updated price target, raised by $1.50, reflects refreshed assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E that appear in recent Street research.Seeking Alpha • May 18
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable
Summary Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings. Despite lumpy revenues and China headwinds, MRVI’s long-term growth prospects and sector correlation support a bullish outlook. Read the full article on Seeking AlphaNarrative Update • May 14
MRVI: Future Upside Will Depend On Executing Updated 2026 Revenue Guidance
Analysts have raised their price targets on Maravai LifeSciences Holdings by increments of $1 and $1.50 after updating models for fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. This Narrative Update reflects those revised inputs.Narrative Update • Apr 28
MRVI: Q4 Beat And Raised Guidance Will Likely Cap Near Term Upside
Analysts have adjusted their view on Maravai LifeSciences Holdings, with the average price target moving from $2 to $3 as updated models incorporate Q4 results that modestly beat consensus and reflect revised assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Even with the price target move to US$3, bearish analysts are signaling that expectations remain restrained.Narrative Update • Apr 12
MRVI: Future Upside Will Depend On Executing Updated 2026 Revenue Outlook
Analysts have lifted their price target on Maravai LifeSciences Holdings to $3 from $2, citing updated models following Q4 results that modestly beat consensus and small tweaks to assumptions around discount rate, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the lift in the price target to $3 as consistent with Q4 results that modestly beat consensus.Narrative Update • Mar 29
MRVI: Future Upside Will Depend On Delivering Updated 2026 Outlook
Analysts recently lifted their price target on Maravai LifeSciences Holdings to $3 from $2, citing updated models after Q4 results that modestly beat consensus and supported adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts view the move to a US$3 price target as better aligned with updated fair value assumptions after Q4 results modestly beat consensus, suggesting expectations are now closer to current execution.Narrative Update • Mar 13
MRVI: Q4 Beat And 2026 Guidance Will Still Restrain Share Upside
Analysts lifted their price target on Maravai LifeSciences Holdings to $3 from $2, citing updated models after Q4 results that modestly beat consensus expectations. Analyst Commentary Analysts framed the higher $3 price target as a recalibration of their models after Q4 results that modestly beat consensus expectations, rather than a shift to a more bullish stance on the stock.Narrative Update • Feb 27
MRVI: Q4 Beat And 2026 Guidance Will Still Leave Shares Vulnerable
Analysts lifted their price target on Maravai LifeSciences Holdings to $3 from $2, citing updated models after Q4 results that modestly beat consensus and adjustments to assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Even with the higher US$3 price target, some bearish analysts remain cautious on how much upside is left relative to execution and growth risks.Narrative Update • Dec 15
MRVI: Future Performance Will Hinge On New Management Amid Ongoing Uncertainty
Analysts have reduced their price target on Maravai LifeSciences Holdings by $1, to $4 from $5, citing a recent revenue miss, low visibility under a new management team, and a view that shares are only suitable for more intrepid investors at current levels. Analyst Commentary Bullish analysts highlight that, despite the recent reset, the new $4 price target still implies meaningful upside from the current $2 to $3 trading range.Analysis Article • Dec 05
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) shares have continued their recent momentum with a 29% gain in the...Narrative Update • Dec 01
MRVI: Shares Will Face Continued Uncertainty With Mixed Outlook Ahead
Analysts have lowered their price target for Maravai LifeSciences Holdings from $5 to $4. This adjustment is due to softer-than-expected third-quarter revenues and ongoing uncertainty under new management.Narrative Update • Nov 17
MRVI: Shares Will Face Ongoing Uncertainty Despite New Management Team
Analysts have revised Maravai LifeSciences Holdings' price target downward from $4.13 to $3.86. This change reflects concerns about lower-than-expected third-quarter revenue and continued low visibility, even though a new management team is in place.Analysis Article • Nov 15
Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Sep 05
Restructuring And mRNA Advances Will Boost Global Prospects
Maravai LifeSciences Holdings’ Future P/E has dropped sharply from 42.69x to 24.20x, reflecting improved earnings prospects or lowered growth expectations, while the fair value (analyst price target) remained unchanged at $4.12. What's in the News Announced an organizational restructuring with a 25% workforce reduction and estimated $8–$9 million in related costs.Analysis Article • Aug 14
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price
NasdaqGS:MRVI 1 Year Share Price vs Fair Value Explore Maravai LifeSciences Holdings's Fair Values from the Community...Analysis Article • Aug 08
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Not Doing Enough For Some Investors As Its Shares Slump 27%
Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) shares have retraced a considerable 27% in the last month...
New Narrative • Mar 24
Flanders Facilities And New Acquisitions Will Create Future Opportunity
Strategic partnerships and new product launches drive diversification and growth across the business.Analysis Article • Feb 08
Positive Sentiment Still Eludes Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Following 25% Share Price Slump
Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) shareholders won't be pleased to see that the share price has had a...Analysis Article • Jan 15
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 43%?
Key Insights Maravai LifeSciences Holdings' estimated fair value is US$7.97 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Nov 25
Maravai LifeSciences: Still Struggling To Find Its Footing
Summary Today, we revisit life sciences concern Maravai LifeSciences Holdings, Inc. as the stock has seen its first insider buying in many years in November. The stock has had a rough go of it during the month after the company lowered FY2024 sales guidance with its third quarter results earlier this month. Maravai was the subject of some takeover chatter in August, but nothing yet has come of those reports. An updated analysis around Maravai LifeSciences follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Nov 11
Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch
The Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) share price has fared very poorly over the last month, falling...Analysis Article • Oct 15
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jul 18
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) shares have had a really impressive month, gaining 29% after a...Analysis Article • Jul 15
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Jul 12
Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Summary Maravai LifeSciences Holdings, Inc. develops drug therapies, diagnostics, and vaccines for global biopharmaceutical companies. Recent sales momentum shows potential sales growth to $300-350 million in FY'25 and FY'26. Despite normalization of sales and earnings, the stock looks fully valued with fairly muted catalysts. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Summary We purchased Maravai shares early in Q3 2023, increased position as stock price dropped, similar to experience with META in 2022. Maravai's subsidiaries, TriLink and Cygnus, play critical roles in NAP and BS segments, with unique assets and capabilities. Maravai's strong margin structure, EBITDA performance, and potential for growth through mRNA applications and quality control testing make it a promising investment. Read the full article on Seeking AlphaAnalysis Article • May 14
Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) shares have continued their recent momentum with a 25% gain in the...Analysis Article • Apr 07
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Maravai LifeSciences Holdings fair value estimate is US$10.38...Analysis Article • Feb 28
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) shares have continued their recent momentum with a 28% gain in the...Shareholder Returns
| MRVI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.6% | -1.5% | -2.8% |
| 1Y | 110.0% | 11.5% | 22.8% |
Return vs Industry: MRVI exceeded the US Life Sciences industry which returned 11.5% over the past year.
Return vs Market: MRVI exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| MRVI volatility | |
|---|---|
| MRVI Average Weekly Movement | 9.9% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRVI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRVI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 416 | Bernd Brust | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI fundamental statistics | |
|---|---|
| Market cap | US$1.30b |
| Earnings (TTM) | -US$104.56m |
| Revenue (TTM) | US$204.73m |
3.6x
P/S Ratio-7.1x
P/E RatioIs MRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI income statement (TTM) | |
|---|---|
| Revenue | US$204.73m |
| Cost of Revenue | US$143.06m |
| Gross Profit | US$61.67m |
| Other Expenses | US$166.23m |
| Earnings | -US$104.56m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 30.12% |
| Net Profit Margin | -51.07% |
| Debt/Equity Ratio | 65.3% |
How did MRVI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 14:48 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Justin Bowers | Deutsche Bank |